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benefit for diabetes patients who do not require insulin. Under the Ontario Public 
Drug Programs (OPDP), these patients have a 200-400 strip/year limit, whereas 
patients who require insulin can receive up to 3,000 strips annually. The policy 
intent was not to change BGTS utilization for insulin patients; however, concerns 
exist around potential negative impacts on diabetes management. The objective of 
this analysis is to quantify the impact of this new BGTS utilization policy in Ontario 
across diabetes patients based on their diabetes treatment. Methods: All patients 
who received BGTS coverage from the OPDP during July 2012 – September 2014 were 
selected for analysis using the IMS Brogan OPDP Database. Annual BGTS utiliza-
tion prior to the policy change (July 2012 – June 2013) was then compared to annual 
BGTS utilization following Ontario’s coverage limit (October 2013 - September 2014). 
Patients were categorized into one of four cohorts based on their diabetes medica-
tion history: ‘insulin only’,’ insulin + oral anti-diabetic (OAD)’, ‘OAD’, or ‘neither’. 
Changes in utilization patterns were assessed for each cohort. Results: 422,525 
patients were identified for the pre-period, and 422,154 patients were identified 
for the post-period. Overall BGTS unit volume declined from 192M to 147M (-24%) 
following the OPDP policy change. On average, the number of BGTS per patient 
per year decreased for ‘OAD ’ and ‘neither’ cohorts by 42% and 54%, respectively. 
Impact to patients managing diabetes with insulin was minimal: ‘insulin only’ (-1%) 
and ‘insulin + OAD’ (-2%). ConClusions: BGTS utilization markedly decreased in 
diabetes patients not managed with insulin; test strip utilization was marginally 
impacted for patients using insulin.
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objeCtives: High flow therapy (HFT) has been demonstrated to be a safe and effec-
tive noninvasive respiratory support technique for the treatment of pre-term infants 
in neonatal intensive care units (NICU). Our objective was to develop a quantita-
tive framework based on available evidence to estimate the economic impact of 
adoption of a HFT respiratory support strategy compared to current standard of 
care. Methods: We constructed a model to estimate total cost per NICU episode 
of care by treatment strategy, considering utilization and duration of the differ-
ent types of ventilatory support modalities – conventional mechanical ventilation 
(CMV), nasal continuous positive airway pressure (nCPAP) ventilation, and HFT – as 
well as utilization levels of surfactant, chest x-rays, blood gas analyses and total 
NICU length of stay. Model parameters were derived from a recent study comparing 
respiratory modality utilization between five US-based neonatal intensive care units 
(NICUs) adopting a HFT strategy and a larger pool of NICUs in the Vermont-Oxford 
Network (VON), and from single center experience. We computed the total cost dif-
ference between the respiratory support strategies based on published cost data. 
Parameter uncertainty was tested in sensitivity analyses. Results: The base case 
analysis resulted in total average length of ventilation of 25.48 days for the non-HFT 
strategy (8.92 days nCPAP, 6.10 days HFT, 10.47 days CMV) and of 25.06 days (2.88 
days nCPAP, 16.86 days HFT, 5.32 days CMV) for the HFT strategy. HFT was associ-
ated with total projected cost savings of $2,317. Results were sensitive to length of 
HFT use, length of CMV, cost of HFT, and length of nCPAP support. ConClusions: 
Adoption of a HFT strategy appears to be associated with meaningful savings in 
total NICU episode of care costs, primarily resulting from reductions in the time of 
conventional mechanical ventilation. Further research is warranted to substanti-
ate these findings.
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objeCtives: To simulate and compare clinical and economic outcomes of self-
monitoring of blood glucose (SMBG) devices along accuracy ranges and strip 
price. Methods: We programmed a long-term type 1 diabetes natural history 
and treatment cost-effectiveness model. In phase one, using In Silico modeling 
validated by the Food and Drug Administration, we associated changes in accu-
racy error rates of SMBG devices to changes in HbA1c (holding hypoglycemic rates 
unchanged) and changes in severe hypoglycemia rates requiring an inpatient stay 
(holding HbA1c levels unchanged). In phase two, using Markov cohort simulation 
modeling, we estimated lifetime clinical and economic outcomes from the Canadian 
payer perspective. The primary comparison was a SMBG device with strip price 
$0.73 Canadian dollars (CAD) with accuracy error rate of 10% versus a SMBG device 
with strip price $0.60 CAD with accuracy error rate of 15%. Outcomes for the aver-
age patient, discounted at 3% per annum, were quality-adjusted life years (QALYs), 
costs, incremental cost-effectiveness ratios (ICERs), and budget impact. Results: 
Assuming the benefits translate into HbA1c improvements only, the ICER with accu-
racy error rate of 10% versus 15% was $11,500 CAD per QALY. Assuming the benefits 
translate into reduced severe hypoglycemic events that required an inpatient stay 
only, an SMBG device with accuracy error rate of 10% dominates (i.e., less costly, 
more effective) an SMBG device with accuracy error rate of 15%. Assuming SMBG 
errors only impact HbA1c improvements, and when varying all inputs simultane-
ously through a probabilistic sensitivity analysis, 91% of simulations were cost-
effective at a willingness-to-pay of $100,000 per QALY. The five-year budget impact 
findings ranged from $0.0005 per member per month for HbA1c improvements to 
cost-savings for severe hypoglycemic event reductions. ConClusions: From the 
efficiency (cost-effectiveness) and affordability (budget impact) payer perspectives, 
reducing the error in SMBG devices appears to be an efficient and affordable strategy.
cases were recruited in our study. Results: The majority of the eligible Medicare 
beneficiaries responded “not at all likely” to take Part D (62%), and significant propor-
tions also reported “not too likely” to take Part D (21.46%), while few of them reported 
“somewhat likely”(9.44%) and “Very likely”(6.31%). Results of weighted cumulative 
logit regression indicated that people who had cost barriers in medication use 
were significantly more likely to take up Medicare Part D (OR= 2.62, 95% CI[2.00, 
3.44], p< 0.001). Males and older adults were less likely to take up Medicare Part D 
(OR= 0.83, 95% CI[0.74, 0.94] and OR= 0.98, 95% CI[0.97, 1.00], p< 0.01). ConClusions: 
Results of this study indicated experiencing CRD was significantly associated with 
the probability of taking up Part D. CRN could be a motivation of taking up Part D. 
Thus, characteristics of beneficiaries who reported having CRN, especially those 
who continued to experience CRN after taking up Part D, need further studies.
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objeCtives: Medication possession ratio (MPR) and persistence are typically 
used as measures of patients’ drug use patterns. However, these measures may 
not capture all aspects related to real world dosing. We aim to explore additional 
approaches to enhance meaningful interpretation of patients’ drug use patterns 
using persistence, adherence and average daily dose (ADD) data of dimethyl fuma-
rate (DF) in a real world dataset. Methods: A retrospective cohort study using the 
MarketScan Commercial and Medicare Databases (March 2013 – January 2014) was 
conducted in adult multiple sclerosis patients. Patients with DF claims who were 
continuously enrolled for at least 9 months before and after starting therapy were 
included (n= 2,879). Outcomes included time to treatment non-persistence (switch 
to another disease modifying therapy (DMT) or drug discontinuation of ≥ 30 days), 
adherence (MPR and percent of days covered (PDC)), and estimated ADD. Data were 
interpreted in the context of the FDA approved daily dosing (240 mg b.i.d.), and an 
earlier trial (1) reporting dose-related MRI findings indicating non-significant effects 
on brain lesions for 360 mg/day and 120 mg/day doses. Results: The mean (SD) 
DF treatment duration was 96 (66) days (median 83) and 24% of patients became 
non-persistent. Mean (SD) MPR and PDC were 0.83 (0.26) and 0.75 (0.29), respectively. 
ADD (SD) was 417 mg/day (221) with 15.3% treated at < 240 mg/day, 5.6% at 240-359 
mg/day, 47.8% at 360-479 mg/day, and 31.3% at ≥ 480 mg/day (i.e., 20.9% treated at 
< 360 mg/day and 68.7% treated at less than the labeled dose). ConClusions: The 
finding of a large proportion of patients receiving potentially sub-optimal treatment, 
as determined by ADD on DF, indicates significant potential clinical consequences 
for these patients. The approach used in this study could be used in other similar 
studies examining treatment adherence to enhance meaningful interpretation of 
adherence data. 1. Lancet 2008; 372(9618):1463-72.
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objeCtives: Knee cartilage damage is a common cause of referral for ortho-
paedic surgery. Treatment aims to reduce pain and symptoms by repairing car-
tilage. Microfracture, the current standard of care, yields good short-term clinical 
outcomes; however, treatment might fail after 2-3 years. A Chitosan-Beta glyc-
erolphosphate bioscaffold is used as an adjunct to microfracture and demonstrates 
improvements in quantity and quality of repaired tissue, potentially reducing the 
risk of treatment failure. This study aimed to establish the economic value of 
bioscaffold versus microfracture alone in knee cartilage repair from the societal 
perspective, using Germany as the reference market. Methods: A decision tree 
with a 20-year time-horizon was constructed, in which undesirable clinical events 
were inferred following initial surgery. These events consisted of pain management, 
surgery and total knee replacement. Clinical outcomes were taken from the pivotal 
clinical trial, supplemented by other literature. Data and assumptions were vali-
dated by an internationally recognized Delphi panel. All relevant resource use and 
costs for procedures and events were considered. Results: In a group of patients 
with all lesion sizes, the model inferred that bioscaffold yields a positive return on 
investment at year 4 (with 20-year cumulative cost savings of € 6,448). Reducing 
the incremental risk of treatment failure gap between bioscaffold and microfrac-
ture by 25% to 50% does not alter this conclusion. Cost savings are greatest for 
patients with large lesions; Results for patients with small lesions are more mod-
est. ConClusions: The Chitosan-Beta glycerolphosphate bioscaffold potentially 
represents a cost-saving alternative for patients with knee cartilage injury by reduc-
ing the risk of clinical events through regeneration of chondral tissue with hyaline 
characteristics. Since the burden of this condition is high, both to the patient and 
society, an effective and economically viable alternative is of importance.
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objeCtives: In August 2013 the Ontario government implemented annual limits 
on the number of blood glucose test strips (BGTS) it will reimburse for people with 
diabetes. The change is based on research that shows BGTS have a limited clinical 
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from pragmatic trials, and another 4 studies (23.5%) from observational studies. 
The odds ratio for effectiveness versus efficacy being cost-effective was 8.75 (95% 
confidence interval; 0.74 to 103.82). ConClusions: Most CEA studies in asthma 
used efficacy data to inform CEA. Studies using effectiveness data trend toward 
being more likely to disseminate cost-effective findings than those using efficacy 
data. Health policy decision makers should pay attention to the type of “E” evidence 
used in CEAs for accurate interpretation and application.
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objeCtives: A cost-effectiveness model can be populated using mortality rates 
from a period’s life-table or using extrapolations of mortality based on historical 
life-tables. Current decision models use the first method. This simulation study aims 
at identifying the impact of mortality methods used on cost effectiveness analy-
ses. Methods: A simulation study was designed based on a two-state Markov model 
(alive-death) that compared a hypothetical intervention against no intervention. The 
model was populated with age-specific, all-cause mortality probabilities from the 
estimation methods presented above. The mortality extrapolations were estimated 
using a smoothed Lee-Carter method. The model outcomes were incremental costs, 
life-years gained (LYG) and incremental net benefit (INB). The proportional difference 
(PD) of the model outcomes between the two mortality estimation methods was the 
outcome of each simulation. The following parameters were simultaneously varied: 
discounting rate (0- 0.05), intervention effect (relative risk of mortality: 0.9-0.99), age 
at intervention (birth- 80 years old), duration of intervention effect (1 year/10 years/ 
lifelong), duration of intervention administration. Simulations were conducted using 
Canadian life-tables. The impact of each parameter on the simulation outcomes was 
estimated using descriptive and graphical methods. Results: The cohorts’ age and 
the discount level had an important effect on the PD in all outcomes (LYG, incremental 
cost and NHB) The duration of intervention effect and administration were more 
influential on the effect of method on the PD of incremental costs and INB. Large 
variation was observed among the scenarios within parameter values, for the PD of 
all outcomes. ConClusions: When using mortality projection methods, substantial 
differences were observed in CEA model outcomes. Given that the magnitude and the 
direction of the impact of mortality estimation methods on the model outcomes is 
multifactorial, decisions on the mortality estimation method used in economic evalu-
ations should be considered after conducting sensitivity analyses using both methods.
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objeCtives: The objective of this study is to examine the prevalence of chronic 
conditions and their impact on the economic burden among cancer survivors in the 
United States. Methods: Using the 2008-2012 Medical Expenditure Panel Survey 
(MEPS) we identified 8,617 cancer survivors and 111,695 individuals without a his-
tory of cancer. Adjusted predictive margins from multivariable regression were used 
to examine the prevalence of chronic conditions. Direct medical costs were meas-
ured using annual health care expenditures and adjusted means were estimated 
using a two-part model. Indirect morbidity costs were calculated from the lost pro-
ductivity due to employment disability, missed work days, and lost household pro-
ductivity and adjusted means were estimated using multivariable logistic regression 
and negative binomial regression modelling. Separate models were used to evaluate 
the impact of each chronic condition and the impact of MCCs. Results: Cancer 
survivors were more likely to have MCCs, with 12.4% reporting ≥ 4 chronic conditions 
compared to 9.3% of individuals without a history of cancer. Medical expenditures 
for cancer survivors with other chronic conditions, particularly those with MCCs 
were higher than among cancer survivors without any of the chronic conditions 
studied. The largest increase in medical expenditures was associated with heart 
disease ($4,287) and stroke ($4,210). Having ≥ 4 chronic conditions was associated 
with increased expenditures of $9,082 per cancer survivor. Lost productivity was 
greater among cancer survivors with other chronic conditions. The largest increase 
in lost productivity was associated with stroke ($4,144) and arthritis ($3,426). Having 
≥ 4 chronic conditions was associated with increased lost productivity of $9,245 
per cancer survivor. ConClusions: Chronic conditions, especially the presence 
of MCCs, are associated with higher medical expenditures and lost productivity 
among cancer survivors. Efforts to reduce the health and economic burden caused 
by chronic conditions among cancer survivors are important given their substantial 
impact on medical expenditures and lost productivity.
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objeCtives: Regression models are the multivariable analytical method of choice 
for epidemiologists and statisticians. It is widely recognized that these models may 
suffer from over-fitting, where the sample estimates fail to generalize to other sam-
ples. Systematic approaches to minimize over-fitting are seldom adopted and there 
is a reluctance to hold data back for independent assessment of model performance. 
This study assesses penalized regressions for reducing over-fitting, cross-validation 
on training data for estimating over-fitting, and the extent to which over-fitting 
produces misleading conclusions. Methods: Data were extracted from the IMS 
PharMetrics Plus US medical claims database for patients with Multiple Sclerosis 
receiving one of two treatments. Cohorts were matched using propensity scoring, 
producing 3,348 matched pairs. The probability of relapse and persistence were 
estimated using standard, stepwise and (LASSO) penalized logistic regressions. 
Over-fitting was measured as the difference between the Area Under Curve (AUC) 
for training and test data and additionally estimated using cross-validation on 
training data alone. Results: Penalized logistic regressions greatly reduced over-
fitting compared to standard and stepwise alternatives, irrespective of the choice 
of response variable and degrees of freedom: for example, modelling relapse with 
50% of the data used for training and 50% used for testing showed overfitting of 
9.9% with standard, 8.0% with stepwise and 3.9% with penalized logistic regression. 
Cross-validation provided reasonable approximations for over-fitting; estimated 
over-fitting for the above standard logistic model was 10.4%. Over-fitting inflated 
the estimated treatment effect by 25% (OR= 2.03 vs. 1.64; standard logistic model 
vs. penalized model). ConClusions: Penalized logistic regression models had 
substantially lower over-fitting. Moreover, good estimates of over-fitting can be 
derived without withholding data. Both penalized regressions and cross-validation 
are straightforward to implement in most statistical packages and greater adoption 
of these methods is encouraged to ensure more reliable estimates of risk factors.
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objeCtives: A state transition model (STM) and a discrete event simulation (DES) 
were developed to evaluate the health outcomes associated with antiplatelet treat-
ments for secondary prevention of thrombotic events for patients with a recent 
myocardial infarction (MI) in the UK. Methods: The STM and DES were devel-
oped with similar assumptions about which events altered risk. In both models, 
results were compared between the vorapaxar plus standard care (VOR) and the 
standard care (SC) arms. Individual patient characteristics at baseline from the quali-
fying MI cohort of TRA 2°P-TIMI 50 trial were used to define patient profiles in both 
models; risk equations developed from the trial were used to estimate MI, stroke, 
and cardiovascular-related death risk. Bleeding event risks, case fatality rates, non-
cardiovascular mortality, and utilities were taken from published studies or UK sta-
tistics. Results: In the base case, for the VOR and SC arms, the DES predicted 13.93 
and 13.70 quality-adjusted life years (QALYs), respectively, versus 12.27 and 11.81 in 
the STM. The DES predicted 0.268 MIs, 0.140 strokes, and 0.318 CV-deaths per patient 
in the VOR arm, and 0.279 MIs, 0.145 strokes, and 0.325 CV-deaths per patient in the 
SC arm. The STM predicted 0.226 MIs, 0.132 strokes, and 0.417 CV-deaths per patient 
in the VOR arm, and 0.234 MIs, 0.136 strokes, and 0.435 CV-deaths per patient in the 
SC arm. ConClusions: Although these two models have very different structures, 
both estimated similar outcomes. The DES predicted more MI and stroke events than 
the STM, as patients can have multiple events in a short time frame rather than one 
event per model cycle. While both approaches are valid, the DES technique offers 
greater flexibility through its ability to consider many risk-changing events without 
“exploding” health states and to track changes in risk factors more efficiently.
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objeCtives: Clinical efficacy or effectiveness (the “E”) is one driver of cost-effec-
tiveness analysis (CEAs). The type of “E” used in each CEA depend on the objectives 
and corresponding data sources. Applying different types of the “E” might affect 
CEA conclusions, but little is known. We aim to test the association of type of “E” 
and cost-effectiveness conclusions using asthma CEAs as an example. Methods: 
A systematic review was performed with 5 electronic databases from 2009 to 2014. 
All CEA studies evaluating asthma medication(s) and reporting incremental cost 
per quality-adjusted life year (QALY) were included. The “E” which was derived from 
an explanatory randomized controlled trial(s) (RCT) or meta-analysis of RCTs was 
defined as efficacy, while the “E” from a pragmatic RCT(s), an observational study, or 
registry was classified as effectiveness. Three times the World Health Organization 
Gross Domestic Product was used to determine a cost-effectiveness willingness-to-
pay threshold per QALY gained. Logistic regression was used to associate type of “E” 
and cost-effectiveness conclusions. Results: A total of 17 CEAs were included. Nine 
studies (52.9%) used efficacy evidence, while 8 studies (47.1%) used effectiveness 
evidence. Ten studies (58.8%) were modeling-based studies, while 7 studies (41.2%) 
were CEA-alongside-clinical trials. The “E” of 5 studies (29.4%) were derived from 
explanatory RCTs, 4 studies (23.5%) from meta-analysis of RCTs, 4 studies (23.5%) 
